Search research articles
Contact Us
Filters
Showing results (561-570 of 601) with videos related to
Page
of 61
Sort By:
JAMA
|
October 28, 2010
Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab
Wendy De Roock, Derek J Jonker, Federica Di Nicolantonio, et al.
Neuro-Oncology Advances
|
November 12, 2021
Impact of lymphopenia on survival for elderly patients with glioblastoma: A secondary analysis of the CCTG CE.6 (EORTC 26062-22061, TROG03.01) randomized clinical trial
Andrew J Song, Keyue Ding, Iyad Alnahhas, et al.
Cancer Research Communications
|
December 5, 2024
Clonal Hematopoiesis of Indeterminate Potential and its Association with Treatment Outcomes and Adverse Events in Patients with Solid Tumors
Tharani Krishnan, Joao Paulo Solar Vasconcelos, Emma Titmuss, et al.
Neuro-Oncology Advances
|
January 31, 2022
Corrigendum to: Impact of lymphopenia on survival for elderly patients with glioblastoma: A secondary analysis of the CCTG CE.6 (EORTC 26062-22061, TROG 08.02) randomized clinical trial
Andrew J Song, Keyue Ding, Iyad Alnahhas, et al.
Therapeutic Advances in Medical Oncology
|
June 30, 2023
Optimizing the number of variants tracked to follow disease burden with circulating tumor DNA assays in metastatic colorectal cancer
Mélina Boutin, James T Topham, Harriet Feilotter, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 11, 2009
Health-related quality of life in patients with advanced colorectal cancer treated with cetuximab: overall and KRAS-specific results of the NCIC CTG and AGITG CO.17 Trial
Heather-Jane Au, Christos S Karapetis, Chris J O'Callaghan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 19, 2007
End points for colon cancer adjuvant trials: observations and recommendations based on individual patient data from 20,898 patients enrolled onto 18 randomized trials from the ACCENT Group
Daniel J Sargent, Smitha Patiyil, Greg Yothers, et al.
British Journal of Cancer
|
December 17, 2013
Epiregulin gene expression as a biomarker of benefit from cetuximab in the treatment of advanced colorectal cancer
D J Jonker, C S Karapetis, C Harbison, et al.
British Journal of Cancer
|
February 24, 2024
Fluoropyrimidine type, patient age, tumour sidedness and mutation status as determinants of benefit in patients with metastatic colorectal cancer treated with EGFR monoclonal antibodies: individual patient data pooled analysis of randomised trials from the ARCAD database
C S Karapetis, H Liu, M J Sorich, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 18, 2022
Neoadjuvant Chemotherapy, Excision, and Observation for Early Rectal Cancer: The Phase II NEO Trial (CCTG CO.28) Primary End Point Results
Hagen F Kennecke, Chris J O'Callaghan, Jonathan M Loree, et al.
Page
of 61
Search research articles
Search
Showing results (561-570 of 601) with videos related to
Sort By:
Page
of 61
JAMA
|
October 28, 2010
Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab
Wendy De Roock, Derek J Jonker, Federica Di Nicolantonio, et al.
Neuro-Oncology Advances
|
November 12, 2021
Impact of lymphopenia on survival for elderly patients with glioblastoma: A secondary analysis of the CCTG CE.6 (EORTC 26062-22061, TROG03.01) randomized clinical trial
Andrew J Song, Keyue Ding, Iyad Alnahhas, et al.
Cancer Research Communications
|
December 5, 2024
Clonal Hematopoiesis of Indeterminate Potential and its Association with Treatment Outcomes and Adverse Events in Patients with Solid Tumors
Tharani Krishnan, Joao Paulo Solar Vasconcelos, Emma Titmuss, et al.
Neuro-Oncology Advances
|
January 31, 2022
Corrigendum to: Impact of lymphopenia on survival for elderly patients with glioblastoma: A secondary analysis of the CCTG CE.6 (EORTC 26062-22061, TROG 08.02) randomized clinical trial
Andrew J Song, Keyue Ding, Iyad Alnahhas, et al.
Therapeutic Advances in Medical Oncology
|
June 30, 2023
Optimizing the number of variants tracked to follow disease burden with circulating tumor DNA assays in metastatic colorectal cancer
Mélina Boutin, James T Topham, Harriet Feilotter, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 11, 2009
Health-related quality of life in patients with advanced colorectal cancer treated with cetuximab: overall and KRAS-specific results of the NCIC CTG and AGITG CO.17 Trial
Heather-Jane Au, Christos S Karapetis, Chris J O'Callaghan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 19, 2007
End points for colon cancer adjuvant trials: observations and recommendations based on individual patient data from 20,898 patients enrolled onto 18 randomized trials from the ACCENT Group
Daniel J Sargent, Smitha Patiyil, Greg Yothers, et al.
British Journal of Cancer
|
December 17, 2013
Epiregulin gene expression as a biomarker of benefit from cetuximab in the treatment of advanced colorectal cancer
D J Jonker, C S Karapetis, C Harbison, et al.
British Journal of Cancer
|
February 24, 2024
Fluoropyrimidine type, patient age, tumour sidedness and mutation status as determinants of benefit in patients with metastatic colorectal cancer treated with EGFR monoclonal antibodies: individual patient data pooled analysis of randomised trials from the ARCAD database
C S Karapetis, H Liu, M J Sorich, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 18, 2022
Neoadjuvant Chemotherapy, Excision, and Observation for Early Rectal Cancer: The Phase II NEO Trial (CCTG CO.28) Primary End Point Results
Hagen F Kennecke, Chris J O'Callaghan, Jonathan M Loree, et al.
Page
of 61